What to Do When Chemotherapy Leaves You Too Weak to Walk

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often debilitating side effect of many anticancer agents—including platinum compounds (e.g., oxaliplatin, cisplatin), taxanes (e.g., paclitaxel, docetaxel), vinca alkaloids (e.g., vincristine), and proteasome inhibitors (e.g., bortezomib). When patients report sudden or progressive leg weakness—particularly difficulty standing, walking, or maintaining balance—it warrants prompt clinical evaluation to distinguish CIPN from other potential causes such as spinal cord compression, electrolyte disturbances, myopathy, or central nervous system involvement.

Peripheral neuropathy typically presents with sensory symptoms first—numbness, tingling, or burning pain in the feet and hands—but motor involvement can follow, especially with certain agents like vincristine or high-dose paclitaxel. Leg weakness in this context often reflects distal symmetric sensorimotor neuropathy, where muscle strength diminishes gradually, beginning in the ankles and feet and potentially progressing proximally. Patients may describe a “heavy” or “rubbery” sensation in the legs, unsteadiness, or frequent stumbling due to impaired proprioception and reduced dorsiflexion strength.

Management begins with a thorough neurological assessment, including evaluation of deep tendon reflexes, vibration and light-touch sensation, gait analysis, and strength testing. Electromyography (EMG) and nerve conduction studies may be indicated if the clinical picture is atypical or progression is rapid. Importantly, no FDA-approved pharmacologic therapy exists specifically for CIPN prevention or reversal; however, dose modification or discontinuation of the offending agent—guided by oncology protocols and risk–benefit discussion—is the cornerstone of intervention. Supportive care includes physical therapy focused on balance training, ankle strengthening, and fall prevention; occupational therapy for adaptive strategies; and judicious use of assistive devices such as ankle-foot orthoses (AFOs) when foot drop is present.

Patients should be counseled that recovery is often slow and incomplete—symptoms may persist for months or years after treatment ends—and that early recognition and multidisciplinary support significantly improve functional outcomes and quality of life. Ongoing research into neuroprotective agents (e.g., duloxetine for symptom management, ongoing trials with acetyl-L-carnitine and glutamine) remains promising but inconclusive to date.